Early mobilization and prehabilitation in patients supported with temporary mechanical circulatory support (tMCS) have emerged as promising strategies to mitigate the deconditioning and sarcopenia associated with critical illness and immobility. While small studies have demonstrated that ambulation with tMCS is both safe and feasible in selected patients, significant variability exists in practice patterns across centers. Implementation of early mobility protocols requires a multidisciplinary team, including cardiology, surgery, critical care, physical therapy, respiratory therapy, nursing, and nutrition supported by dedicated personnel, familiar with the unique considerations of tMCS devices. Despite increasing adoption, there remains a paucity of high-quality data evaluating the impact of early ambulation on clinical outcomes, functional recovery, and candidacy for advanced therapies. This review outlines current practices, key challenges, and emerging strategies in tMCS rehabilitation and calls for standardized protocols and prospective studies to guide optimal implementation across institutions.

Sacubitril/valsartan is a foundational component of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), demonstrating reductions in cardiovascular mortality and hospitalization in PARADIGM-HF. The introduction of generic sacubitril/valsartan was expected to improve affordability and expand access. However, real-world experience suggests that financial and administrative barriers persist despite generic availability. High deductibles under Medicare Part D, variable formulary placement, loss of manufacturer copay assistance, prior authorization requirements, and digital enrollment barriers continue to disrupt therapy continuity. These obstacles disproportionately affect elderly and socioeconomically vulnerable patients and contribute to cost-related nonadherence, treatment interruption and 'financial toxicity': the negative effects of the economic burden of medical care on patients. From a frontline clinical perspective, financial toxicity functions as a modifiable risk factor in HFrEF management. Aligning benefit design with evidence-based care is necessary to ensure that generic availability translates into sustained access and clinical benefit.